GSK‐3β Cancer Research Results

GSK‐3β, Glycogen synthase kinase (GSK)3β: Click to Expand ⟱
Source:
Type:
GSK3β is a crucial member of the Wnt/β-catenin-, hedgehog (Hh)-, notch- and c-myc-mediated major pro-oncogenic pathways, while also being a negative regulator of epithelial–mesenchymal transition (EMT). Accumulating evidence defines GSK3β as a potential therapeutic target in cancer, thus encouraging the development of GSK3β inhibitors for cancer treatment.
Glycogen synthase kinase 3 beta (GSK-3β) is a serine/threonine kinase that plays a crucial role in various cellular processes, including cell proliferation, differentiation, and apoptosis. Its expression and activity have been implicated in several types of cancer, often with varying prognostic implications.

In many cancers, decreased GSK-3β activity is associated with poor prognosis, while in others, increased activity may correlate with aggressive disease.


Liver, Liver Cancer: Click to Expand ⟱
Liver Cancer
Scientific Papers found: Click to Expand⟱
5434- AG,    Recent Advances in the Mechanisms and Applications of Astragalus Polysaccharides in Liver Cancer Treatment: An Overview
- Review, Liver, NA
AntiCan↑, Apoptosis↑, TumCP↓, EMT↓, Imm↑, ChemoSen↑, BioAv↓, TumCG↓, IL2↑, IL12↑, TNF-α↑, P-gp↓, MDR1↓, QoL↑, Casp↑, DNAdam↑, Bcl-2↓, BAX↑, MMP↓, Cyt‑c↑, NOTCH1↓, GSK‐3β↓, TumCCA↑, GSH↓, ROS↑, lipid-P↑, c-Iron↑, GPx4↓, ACSL4↑, Ferroptosis↑, Wnt↓, β-catenin/ZEB1↓, cycD1/CCND1↓, Akt↓, PI3K↓, mTOR↓, CXCR4↓, Vim↓, PD-L1↓, eff↑, eff↑, ChemoSen↑, ChemoSen↑, chemoP↑,
2922- LT,    Combination of transcriptomic and proteomic approaches helps unravel the mechanisms of luteolin in inducing liver cancer cell death via targeting AKT1 and SRC
- in-vitro, Liver, HUH7
Half-Life↝, TumCCA↑, AKT1↓, ATF2↓, NF-kB↓, GSK‐3β↓, cMyc↓, GSTs↓, TrxR1↓, ROS↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 1,   GSTs↓, 1,   c-Iron↑, 1,   lipid-P↑, 1,   ROS↑, 2,   TrxR1↓, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Core Metabolism/Glycolysis ⓘ

ACSL4↑, 1,   AKT1↓, 1,   cMyc↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   ATF2↓, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp↑, 1,   Cyt‑c↑, 1,   Ferroptosis↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 1,   GSK‐3β↓, 2,   mTOR↓, 1,   NOTCH1↓, 1,   PI3K↓, 1,   TumCG↓, 1,   Wnt↓, 1,  

Migration ⓘ

TumCP↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Barriers & Transport ⓘ

P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

CXCR4↓, 1,   IL12↑, 1,   IL2↑, 1,   Imm↑, 1,   NF-kB↓, 1,   PD-L1↓, 1,   TNF-α↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 1,   ChemoSen↑, 3,   eff↑, 2,   Half-Life↝, 1,   MDR1↓, 1,  

Clinical Biomarkers ⓘ

PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   chemoP↑, 1,   QoL↑, 1,  
Total Targets: 50

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: GSK‐3β, Glycogen synthase kinase (GSK)3β
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:14  Cells:%  prod#:%  Target#:385  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page